Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salbutamol - concentrate for solution for infusion - 1 milligram(s)/millilitre - selective beta-2-adrenoreceptor agonists; salbutamol

Marekani - Kiingereza - NLM (National Library of Medicine)

dispensing solutions inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relations

Singapoo - Kiingereza - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - salbutamol sulphate eqv salbutamol - solution - 0.5% w/v - salbutamol sulphate eqv salbutamol 0.5% w/v

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pco manufacturing - salbutamol sulfate - nebuliser solution - 2.5 milligram

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

b & s healthcare - salbutamol sulfate - nebuliser solution - 2.5 milligram

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salbutamol sulfate - nebuliser solution - 5mg/ml mg/ml

Saudi - Kiingereza - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia, saudi arabia - salbutamol - nebuliser solution - 0.5 %

Saudi - Kiingereza - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia, saudi arabia - salbutamol - nebuliser solution - 0.5 %

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 2.4 mg/ml (equivalent: salbutamol, qty 2 mg/ml) - inhalation - excipient ingredients: sodium chloride; sulfuric acid; water for injections - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 1.2 mg/ml (equivalent: salbutamol, qty 1 mg/ml) - inhalation - excipient ingredients: sodium chloride; water for injections; sulfuric acid - indications as at 1st february 1999: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma or in other situations known to induce bronchospasm.